Atorvastatin increases the expression of long non-coding rnas arsr and chrome in hypercholesterolemic patients: A pilot study
Author
dc.contributor.author
Páez, Isis
Author
dc.contributor.author
Prado, Yalena
Author
dc.contributor.author
Ubilla, Carmen G.
Author
dc.contributor.author
Zambrano Coloma, Tomás
Author
dc.contributor.author
Salazar, Luis A.
Admission date
dc.date.accessioned
2021-05-13T20:19:40Z
Available date
dc.date.available
2021-05-13T20:19:40Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Pharmaceuticals 2020, 13, 382
es_ES
Identifier
dc.identifier.other
10.3390/ph13110382
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/179605
Abstract
dc.description.abstract
Atorvastatin is extensively used to treat hypercholesterolemia. However, the wide interindividual variability observed in response to this drug still needs further elucidation. Nowadays, the biology of long non-coding RNAs (lncRNAs) is better understood, and some of these molecules have been related to cholesterol metabolism. Therefore, they could provide additional information on variability in response to statins. The objective of this research was to evaluate the effect of atorvastatin on three lncRNAs (lncRNA ARSR: Activated in renal cell carcinoma (RCC) with sunitinib resistance, ENST00000424980; lncRNA LASER: lipid associated single nucleotide polymorphism locus, ENSG00000237937; and lncRNA CHROME: cholesterol homeostasis regulator of miRNA expression, ENSG00000223960) associated with genes involved in cholesterol metabolism as predictors of lipid-lowering therapy performance. Twenty hypercholesterolemic patients were treated for four weeks with atorvastatin (20 mg/day). The lipid profile was determined before and after drug administration using conventional assays. The expression of lncRNAs was assessed in peripheral blood samples by RT-qPCR. As expected, atorvastatin improved the lipid profile, decreasing total cholesterol, LDL-C, and the TC/HDL-C ratio (p < 0.0001) while increasing the expression of lncRNAs ARSR and CHROME (p < 0.0001) upon completion of treatment. LASER did not show significant differences among the groups (p = 0.50). Our results indicate that atorvastatin modulates the expression of cholesterol-related lncRNAs differentially, suggesting that these molecules play a role in the variability of response to this drug; however, additional studies are needed to disclose the implication of this differential regulation on statin response.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT
1171765
Direccion de Investigacion of the Universidad de La Frontera
DI11-0063
Conicyt -Chile Doctoral Scholarship